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Abstract
Objective: Previous studies have associated Guillain–Barre syndrome (GBS)
with Zika virus (ZIKV) outbreaks in South America and Oceania. In Asia,
ZIKV is known to circulate widely, but the association with Guillain–Barre syn-
drome is unclear. We investigated whether endemic ZIKV infection is associ-
ated with the development of GBS. Methods: A prospective study was
conducted from 2011 to 2015 in Bangladesh. A total of 418 patients and 418
healthy family controls were included in the study. Patients were diagnosed
with GBS prior to inclusion according to established criteria. Detailed informa-
tion on the epidemiology, clinical presentation, electrophysiology, diagnosis,
disease severity, and clinical course were obtained during a follow-up of 1 year
using a predefined protocol. Results: ZIKV-neutralizing antibodies were
detected in our study from 2013 onwards. The prevalence of ZIKV-neutralizing
antibodies was not significantly higher in patients with GBS compared to
healthy controls (OR 2.23, P = 0.14, 95% CI 0.77–6.53). Serological evidence
for prior ZIKV infection in patients with GBS was associated with more fre-
quent cranial, sensory, and autonomic nerve involvement compared to GBS
patients with Campylobacter jejuni, the predominant preceding infection in GBS
worldwide. Nerve-conduction studies revealed that ZIKV antibodies were asso-
ciated with a demyelinating subtype of GBS, while C. jejuni infections were
related to an axonal subtype. Interpretation: No significant association was
found between ZIKV infection and GBS in Bangladesh, but GBS following
ZIKV infection was characterized by a distinct clinical and electrophysiological
subtype compared to C. jejuni infection. These findings indicate that ZIKV may
precede a specific GBS subtype but the risk is low.
Introduction
Major outbreaks of Zika virus (ZIKV), a mosquito-borne
neurotropic flavivirus, have been reported in the island of
Yap (2007), French Polynesia (2013–2014), and several
Latin-American countries (2014).1–4 During the ZIKV
outbreak in French Polynesia, a profound 20-fold increase
in the number of Guillain–Barre syndrome (GBS) was
reported.5 GBS is an acute polyradiculoneuropathy caus-
ing a rapidly progressive limb weakness and is triggered
by various types of preceding infection.6 Recently, the
association between ZIKV and GBS has also been
reported in various Latin-American countries following
outbreaks of ZIKV.4,7–9 In Asia, where ZIKV has been
endemic for several decades,10–12 the occurrence of GBS
and other neurological complications after ZIKV infection
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have thus far not been reported. The frequency of ZIKV
infections in endemic areas is lower than during out-
breaks, but considering the size and continuity of the
exposed population, a considerable number of people in
Asia are expected to be at risk to develop GBS.
GBS is a heterogeneous disorder of which the correct
clinical diagnosis and classification may be challenging.13
The disease diversity is associated with the variety in pre-
ceding infections. Campylobacter jejuni is the predominant
infection triggering GBS worldwide,14 and is associated
with severe acute motor axonal neuropathy (AMAN)-type
of GBS with a poor clinical outcome.15 Cytomegalovirus
in contrast can cause severe senso-motoric disorders and
a GBS subtype described as acute inflammatory demyeli-
nating polyneuropathy (AIDP).16 The frequency of these
GBS subtypes differs between geographical regions, which
is in part explained by the local endemic infections.
In our study, we assessed whether endemic circulation
of ZIKV in Bangladesh is associated with the development
of GBS in a well-defined prospective case–control study.
We compared the clinical phenotype and electrophysio-
logical classification of GBS cases with detected ZIKV-
neutralizing antibodies versus GBS cases with a preceding
C. jejuni infection.
Materials and Methods
Study design
Four hundred and eighteen patients with GBS were
prospectively included at Dhaka Medical College and
Hospital (DMCH) or the National Institute of Neuro-
science (NINS) in Dhaka, Bangladesh. The first 250
patients were included between January 2011 and June
2013. The remaining 168 patients were included as part
of the ongoing International GBS Outcome Study (IGOS)
between November 2013 and December 2015.17
A clinical neurologist examined all eligible patients
within 2 days of admission.
The patients were included in the study after the vali-
dation of the clinical diagnosis using the criteria defined
by NINDS.18 Detailed, standardized information on
demographic and clinical data were collected, including
age, sex, place of residence (district of Bangladesh); clini-
cal symptoms of preceding infections or other events;
time and degree of maximum weakness; cranial, sensory,
and autonomic nerve involvement; respiratory failure;
and requirement for mechanical ventilation. Disease
severity was evaluated using the GBS disability score,19 a
widely accepted scoring system used to assess functional
status. It is scored as 0: normal; 1: minor symptoms and
capable of running; 2: can walk 10 m or more without
assistance but unable to run; 3: can walk 10 m across an
open space with help; 4: bedridden or chair-bound; 5:
requiring assisted ventilation for at least part of the day,
6: death. The diagnosis in all patients was classified
according to the GBS criteria of the Brighton Collabora-
tion, ranging from level 1 (highest level of diagnostic cer-
tainty) to level 4 (reported as Guillain–Barre syndrome,
possibly due to insufficient data for further classification).
Blood and CSF were collected upon admission follow-
ing local laboratory standards and prior to any possible
treatment; a protein level ≤0.45 g/L and a cell count ≤5/
lL was categorized as normal. NCS was performed by a
trained clinical electrophysiologist, usually within 10–
14 days of onset of weakness, and classified as AIDP,
AMAN, motor and sensory axonal (AMSAN), unclassi-
fied, or normal.20 Patients were frequently re-examined
and followed up for 1 year to exclude the possibility of
alternative diagnoses.
For each GBS patient, a household healthy control
(HC) was identified and included. A HC was defined as a
healthy family member older than 15 years and living in
the same household. Blood samples of the HC were col-
lected upon inclusion of the GBS patient.
Ethical consideration
All project protocols were reviewed and approved by the
institutional review board and ethical committees at
ICDDR,B and Dhaka Medical College and Hospital, Ban-
gladesh (PR-13061). The IGOS protocol was also reviewed
and approved by the institutional review board of Eras-
mus MC (MEC-2011-477). Written informed consent was
obtained from participants or their legal representatives.
Serology
Presence of ZIKV-reactive IgM and IgG antibodies was
assessed by the NS1 ELISA assay (EuroimmunTM, L€ubeck,
Germany)21 for all patient and HC sera following manu-
facturers’ instructions at the Department of Virology,
Erasmus MC, Rotterdam, the Netherlands. All sera with
borderline or detectable ZIKV NS1-IgM and/or NS1-IgG
antibodies were confirmed by in-house ZIKV micro-VNT
(Virus Neutralisation Test; Erasmus MC). For ZIKV
micro-VNT test, twofold serum dilutions were incubated
with 100 TCID50 of ZIKV Suriname strain 2016 102
(Genbank reference KU937936, EVAg Ref-SKU: 011V-
01621) at 37°C, and used to inoculate Vero cells for
5 days at 37°C. ZIKV infection was determined by cyto-
pathic effect. A reciprocal VNT ZIKV titer of ≥1/32 was
considered positive. DENV NS1 IgG ELISAs (Euroim-
munTM) were performed for all patient sera and all ZIKV
NS1 IgG-positive HC sera. Antibodies against C. jejuni
were determined for all patient sera using an indirect IgG
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ELISA and antibody class capture ELISAs for IgM and
IgA antibodies at the Department of Medical Microbiol-
ogy, Reinier de Graaf Gasthuis, Delft, The Netherlands, as
previously described.22
ZIKV quantitative real-time polymerase
chain reaction
Viral loads of all patient samples, and all HC sera with
equivocal or positive ZIKV IgM, were tested by quantita-
tive real-time polymerase chain reaction (qRT-PCR) tar-
geting both the Asian and African ZIKV lineage
(ZIKV_1086_fwd, ZIKV_1107_probe and ZIKV_1162c).23
The MagnaPureLC system (Roche Diagnostics, Almere,
The Netherlands) was used to extract total nucleic acid
from 50 lL serum.
Statistical analyses
Quantitative variables are presented as number (percent-
age), mean, and standard deviation or median. Differ-
ences in sex and age categories between GBS patients and
healthy controls were examined using the McNemar test.
To compare the differences in (virus neutralizing) anti-
bodies between the different years, we used a chi-square
test with a categorical outcome variable. Differences in
the proportion of individuals with ZIKV neutralizing
antibodies in GBS patients versus healthy controls were
tested using an univariate conditional logistic regression
analysis, adjusted for age as a categorical variable. Clinical
characteristics between three groups of GBS patients were
compared: group A (only ZIKV neutralizing antibodies),
group B (only evidence of recent C. jejuni infection) and
group C (no antibodies detected against ZIKV and C.
jejuni). A Chi-square was used, and a Fischer’s exact test
if appropirate. All statistical tests were performed using
IBM SPSS version 22.0 (Armonk, NY, USA).
Results
GBS and HC cohort description
Four hundred and eighteen patients with GBS and 418
HC were prospectively included from 2011 to 2015.
Their characteristics are provided in Table 1. GBS
patients were predominantly young adult males (64%)
with a median age of 27 years (IQR, 16–41). They did
not differ from HC with respect to sex and time of
blood sampling, but HC were older as children younger
than 15 years old were not included in the control
group. Among GBS patients, diarrhea (44%) was the
most commonly preceding event, followed by respiratory
symptoms (18%) and diverse clinical signs like fever and
rash (8%); 21% of patients did not report any clinical
signs prior to neurological symptoms. The severity of
neurological symptoms upon hospital admission was
assessed using the GBS disability score:19 341/418 (82%)
of patients were bedbound (score of 4 or 5), of whom
80/341 (19%) required mechanical ventilation (score of
5). Fifty-six patients (14%) died within 1 year after the
diagnosis (score 6). NCS was conducted on 306/418
patients; 183/306 (60%) of all cases were classified as
AMAN or AMSAN and 84/306 (28%) as AIDP. The
patients were also classified according to the Brighton
diagnostic criteria for GBS. Brighton level 1 was met in
246 (59%) patients, level 2 in 136 (32%) patients, level 3
in 23 (6%) patients, and level 4 in 8 (2%) patients (data
not shown). Five patients could not be classified as they
presented a variant of GBS with exaggerated deep tendon
reflexes in weak limbs. In these five patients, other diag-
nosis were excluded, all had albumin-cytological dissocia-
tion and the three cases who had undergone NCS
showed motor axonal neuropathy.
ZIKV infection in GBS versus HC
Serological analyses for all 418 patients are presented in
Figure 1. The first GBS patient with detectable ZIKV-neu-
tralizing antibodies was included in the study in December
2013. In 2014, 16 of 92 (17%) patients had detectable
ZIKV IgG antibodies of which 12/16 (75%) were con-
firmed by virus neutralization. In 2015, ZIKV IgG antibod-
ies were detected in 15 of 52 (28%) of GBS patients and
were confirmed by virus neutralization in 5 of 15 (33%).
The seroprevalence of anti-DENV IgG in GBS patients
increased significantly from 35% in 2011 to 55% in 2012
(P = 0.01), but stabilized between 2013 and 2015 (Fig. 1).
Table 2 depicts an increased detection rate of ZIKV-
neutralizing antibodies in GBS patients (18/418), but this
difference was not significant by conditional logistic
regression analysis when compared to HC (13/418) (OR
2.23, 95% CI 0.77–6.53, P = 0.14). Of the 18 GBS
patients with ZIKV-neutralizing antibodies, one patient
had IgM antibodies against ZIKV (indicative of a recent
infection) versus three of the HC (data not shown). We
did not detect ZIKV genome in the serum of any of the
GBS patients (Table 3).
ZIKV-associated GBS subtype
An in-depth analysis was performed on the 18 patients
with GBS who presented with ZIKV-neutralizing antibod-
ies during 2013–2015. IgA and/or IgM antibodies against
C. jejuni were identified in 9/18 patients (Table 3),
suggesting recent (co-)infection.22 All patients with sero-
logical evidence of a recent C. jejuni (co-)infection
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clinically presented with a pure motor subtype of GBS, in
line with previous reports from Bangladesh.15 In contrast,
6/9 patients with ZIKV-neutralizing antibodies but no
evidence of recent C. jejuni infection clinically presented
with the sensory-motor subtype, with cranial nerve
involvement (8/9) and autonomic dysfunction (5/9). By
electrophysiology, 4/9 GBS cases with recent C. jejuni (co-
)infection were classified as AMAN, whereas 5/7 GBS
cases with ZIKV-neutralizing antibodies were classified as
AIDP. All 18 patients with ZIKV-neutralizing antibodies
presented with the classical tetraparesis (data not shown);
14 were severely affected with a nadir disability score of 4
or 5; however, 13 recovered well and could walk indepen-
dently at 3 months follow-up. Of these 13 patients, eight
did not receive specific therapy (intravenous
immunoglobulin [IVIG] or plasmapheresis) but only
Table 1. Characteristics of 418 GBS patients and 418 healthy family controls.
GBS Healthy controls P-value
Total number 418 418
Sex 0.11
Male 266 (63.6%) 231 (58.2%)
Female 152 (36.4%) 164 (41.3%)
Median age (range) 27 (0–75) 34 (17–75)
Age category (years)
<15 101 (24.2%) 0 (0.0%) <0.001
16–30 146 (34.9%) 156 (41.5%)
31–45 97 (23.2%) 169 (44.9%)
> 45 74 (17.7%) 51 (13.6%)
Antecedent symptoms
Diarrhea 184 (44.0%)
Respiratory 76 (18.2%)
Others1 34 (8.1%)
None 86 (20.6%)
Unknown 35 (8.4%)
Neurological symptoms
Cranial nerve impairment 273 (65.3%)
Sensory deficits 124 (29.7%)
Ataxia 59 (14.2%)
Autonomic dysfunction 96 (23.0%)
Days from onset symptoms to inclusion 18.8 (10.1)
Days from onset weakness to inclusion 10.6 (7.9)
GBS score at entry
0-1 2 (0.4%)
2 24 (5.7%)
3 51 (12.2%)
4 261 (62.4%)
5 80 (19.1%)
Last known GBS score (1 year after diagnosis)
0 122 (29.8%)
1 97 (23.7%)
2 94 (23.0%)
3 27 (6.6%)
4 13 (3.2%)
5 -
6 56 (13.7%)
Electrophysiology
AMAN 157 (51.3%)
AMSAN 26 (8.5%)
AIDP 84 (27.5%)
Unclassified 35 (11.4%)
Normal 4 (1.3%)
Data are presented as numbers (proportions) or mean (SD).
1Others: other mentioned clinical symptoms included fever, rash, dysuria.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 609
C.H. GeurtsvanKessel et al. Zika Virus and Guillain–Barre Syndrome
supportive care. One patient was treated with small vol-
ume plasma exchange and four received IVIG.
To test whether GBS patients with a putative antece-
dent ZIKV infection presented with distinct clinical and
electrophysiological features, we compared the clinical
parameters of the 18 GBS patients with ZIKV-neutralizing
antibodies to those of all patients with serological evi-
dence of Campylobacter infection. One hundred and
forty-one consecutive patients included from 2013
onward (the year of ZIKV introduction to the cohort)
were eligible. Table 4 depicts the clinical and electrophysi-
ological characteristics of three subgroups: (1) patients
with ZIKV-neutralizing antibodies and no detectable IgA/
IgM antibodies against Campylobacter (9/141; 6%), (2)
patients without neutralizing antibodies against ZIKV but
with IgA/IgM antibodies against Campylobacter (74/141;
52%), and (3) patients in whom neither ZIKV nor C. je-
juni antibodies were detected (58/141; 41%). Patients with
ZIKV-neutralizing antibodies were significantly older than
patients with evidence of recent Campylobacter infection
(P = 0.002). Cranial nerves were impaired in all three
subgroups of patients; however, sensory deficits and
autonomic dysfunction were reported significantly more
often in ZIKV-related GBS than Campylobacter-related
GBS (P = 0.02). Electrophysiological patterns also dif-
fered: 36/49 (74%) of Campylobacter-related cases were
classified as AMAN versus 1/6 (17%) of ZIKV-related
cases (Table 4; P = 0.01). In contrast, 3/6 (50%) ZIKV-
related cases were classified as AIDP versus 6/49 (12%) of
Campylobacter-related cases. The outcome of ZIKV-
related GBS appeared more favorable than Campylobac-
ter-related GBS (GBS disability scores of 0–2 in 88% vs.
66%, respectively; Table 4).
Discussion
This is the first prospective and systematic study from a
country with endemic ZIKV circulation, to investigate the
association between ZIKV infection and GBS. Our find-
ings indicate that ZIKV is circulating in Bangladesh since
2013 and that ZIKV-neutralizing antibodies can be
detected in up to 10% of the study population. We
observed that ZIKV-neutralizing antibodies did not
appear more frequently in GBS patients than in HC (OR
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Figure 1. Seroprevalence of DENV and ZIKV antibodies in 418 GBS patients 2011–2015. The bars represent the percentage of GBS patients with
IgG antibodies against ZIKV (gray), in red the percentage of patients with antibodies confirmed by virus neutralization. P-values in red above the
bars are related to the differences in virus-neutralizing antibody titers. Triangles represent the percentage of GBS patients with IgG antibodies
against DENV. P-values in black above the triangles are related to the differences in DENV IgG. Bold numbers represent P<0.05
Table 2. Frequency of ZIKV-neutralizing antibodies in 418 GBS patients and 418 case-matched healthy family controls over time.
2011 2012 2013 2014 2015 2011–2015
No of patients with GBS 112 104 58 92 52 418
GBS (%) 0 0 1 (1.7%) 12 (13.2%) 5 (9.6%) 18 (4.3%)
Healthy controls (%) 0 0 0 (0%) 7 (7.7%) 6 (11.5%) 13 (3.1%)
Odds ratio – – – – – 2.23
95% CI – – – – – 0.77–6.53
P-value – – – – – 0.14
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Table 4. Comparison of the clinical characteristics of GBS patients from 2013 to 2015 (n = 141) stratified by serological response to ZIKV and
Campylobacter jejuni.
A B C
P-value
ZIKV
VNT-positive (n = 9)
C. jejuni IgM-
and/or IgA-positive
(n = 74)
ZIKV- & C. jejuni-
negative (n = 58) A versus B A versus C
Sex 0.07 0.43
Male 8 (88.9%) 40 (54.1%) 42 (72.4%)
Female 1 (11.1%) 34 (45.9%) 16 (27.6%)
Median age (range) 50.00 (27–59) 23.00 (0–72) 30.00 (0–60)
Age category (years) 0.002 0.02
<15 0 (0.0%) 24 (32.4%) 12 (20.7%)
16–30 1 (11.1%) 28 (37.8%) 18 (31.0%)
31–45 2 (22.2%) 10 (13.5%) 17 (29.3%)
> 45 6 (66.7%) 12 (16.2%) 11 (19.0%)
Antecedent infection or event 0.24 0.62
Diarrhea 2 (22.2%) 33 (44.6%) 12 (20.7%)
Respiratory symptoms 0 (0.0%) 6 (8.1%) 11 (19.0%)
Other 0 (0.0%) 3 (4.1%) 2 (3.4%)
None 4 (44.4%) 24 (32.4%) 20 (34.5%)
Unknown 3 (33.3%) 8 (10.8%) 13 (22.4%)
Neurological symptoms
Cranial nerve impairment 8 (88.9%) 41 (55.4%) 40 (69.0%) 0.08 0.43
Sensory deficits 4 (44.4%) 8 (10.8%) 26 (44.8%) 0.02 0.92
Ataxia 0 (0.0%) 1 (1.4%) 10 (17.2%) 0.32 0.02
Autonomic dysfunction 5 (55.6%) 13 (17.6%) 12 (20.7%) 0.02 0.04
Mean number of days between the onset of
preceding symptoms and signs, and study
inclusion (SD)
16.80 (9.63) 16.86 (8.23) 21.84 (11.40) 0.99 0.35
Mean number of days between the onset
of weakness and study inclusion (SD) 7.33 (3.28) 8.43 (4.16) 10.90 (6.40) 0.45 0.11
GBS score at entry 0.41 0.43
0 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 0 (0.0%) 0 (0.0%) 1 (1.7%)
2 0 (0.0%) 7 (9.5%) 5 (8.6%)
3 2 (22.2%) 9 (12.2%) 5 (8.6%)
4 4 (44.4%) 45 (60.8%) 37 (63.8%)
5 3 (33.3%) 13 (17.6%) 10 (17.2%)
Last known GBS score (within 1 year) 0.42 0.96
0 3 (33.3%) 7 (9.5%) 14 (24.1%)
1 3 (33.3%) 21 (28.4%) 21 (36.2%)
2 2 (22.2%) 21 (28.4%) 11 (19.0%)
3 0 (0.0%) 14 (18.9%) 1 (1.7%)
4 0 (0.0%) 2 (2.7%) 4 (6.9%)
5 0 (0.0%) 1 (1.4%) 2 (3.4%)
6 1 (11.1%) 8 (10.8%) 5 (8.6%)
EMG type 0.01 0.71
AMAN 1 (16.7%) 36 (73.5%) 9 (29.0%)
AMSAN 2 (33.3%) 3 (6.1%) 4 (12.9%)
AIDP 3 (50.0%) 6 (12.2%) 15 (48.4%)
Unclassified 0 (0.0%) 4 (8.2%) 2 (6.5%)
Normal 0 (0.0%) 0 (0.0%) 1 (3.2%)
The P-values depicted in bold represent P< 0.05
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2.23, 95% CI 0.77–6.53, P = 0.14). GBS patients with
ZIKV-neutralizing antibodies mostly presented with a
clinical and electrophysiological phenotype that is distinct
from the predominant phenotype worldwide associated
with C. jejuni. These findings indicate that ZIKV may
precede a specific GBS subtype but that the risk is low.
Up to present, studies describing the role of ZIKV in
GBS have focused on outbreak areas and symptomatic
ZIKV patients.4,5,8,9,24–27 Interestingly, ZIKV infections are
symptomatic in only an estimated 20% of cases and ZIKV
will probably soon be endemic in most affected areas. In
addition, not all previous studies were originally set-up to
study the association between ZIKV and GBS and there-
fore have several limitations. Most studies were retrospec-
tive, restricting the accuracy of GBS diagnosis. Only few
studies used an adequate case–control design and specific
data on the clinical and electrophysiological subtype of
GBS and on other preceding infections are often lacking.
In our study, we certified the accuracy of GBS diagnosis
by applying the Brighton case definitions criteria and an
extensive standardized follow-up period.
In accordance with our earlier report from Bangladesh,15
there was a considerable delay before the GBS patients
reached the hospital (an average of 11 days after onset of
weakness). This delay resulted in a large mean interval
between a possible antecedent infection and specimen col-
lection (19 days), which is important when interpreting
the results of the diagnostic assays. It is a plausible explana-
tion for not detecting ZIKV genome by PCR in serum. The
assessment of ZIKV in urine or whole blood would have
been a valuable addition to the study protocol and should
be considered in future studies.28 The lack of detected IgM
responses may be due to the limited sensitivity of the sero-
logical method used for IgM detection (Euroimmun ZIKV
ELISA).29,30 Furthermore, IgM responses can be attenuated
in infected individuals with flavivirus infections in the
past31–33 and ZIKV serology is further complicated by
extensive cross-reactivity with other endemic fla-
viviruses.21,34 As virus-specific neutralizing antibody testing
has been suggested the most definitive tool to confirm the
presence of ZIKV-specific antibodies, we performed ZIKV
neutralization assays on all sera with detectable ZIKV IgG
antibodies. The specificity of the detected ZIKV-neutraliz-
ing antibodies is supported by the kinetics of the DENV
IgG antibodies in our study.
The first study reporting on the association between
ZIKV and GBS indicated that ZIKV infections were exclu-
sively associated with axonal GBS, whereas recent reports
from Brazil and Colombia show that AIDP is the subtype
of GBS associated with ZIKV infection.5,8,25–27 Some of
this variety may be attributed to retrospective analysis of
nonstandardized clinical and electrophysiological data to
describe subtypes of GBS. In our study, all included GBS
patients fulfilled the NINDS-criteria for the diagnosis of
GBS.18 We performed subgroup analysis of our GBS
cohort to compare the clinical and electrophysiological
characteristics of patients with evidence of ZIKV infection
versus recent C. jejuni infection, although the subgroups
are small. Patients with C. jejuni-associated GBS without
ZIKV-neutralizing antibodies developed the pure motor
form of GBS more often than patients with evidence of
ZIKV infection without evidence of a recent C. jejuni
infection. The latter patients predominantly developed a
sensory-motor form of GBS. In addition, we demon-
strated that patients with both ZIKV-neutralizing anti-
bodies and recent C. jejuni infection all developed a pure
motor type of GBS and usually the axonal type, empha-
sizing the need for C. jejuni testing in patients who
develop GBS following ZIKV infection.
This study has several limitations. First, confirmation
of a preceding ZIKV infection in GBS patients is generally
complicated by the delay between infection and the first
neurological manifestations of GBS as mentioned in pre-
vious studies.4,35 In this study, there was an additional
delay between this neurological onset and hospital admis-
sion that further reduced the chances of demonstrating
the viral genome in serum. Therefore, serological tests
were used for the analyses in this study which demon-
strated ZIKV-specific antibodies by the gold standard
method – virus-specific neutralization. Second, we choose
to use case-matched HC from the same family and house-
hold, as they live in the same geographic area and are
likely to have the same socio-economic status. It is thus
expected that they were equally exposed to mosquitoes
which might have decreased the OR. Third, HC were sig-
nificantly older than the GBS patients, but correcting for
age in the analyses did not affect the statistical outcome.
Finally, the performed study is an observational study.
Although a first report on circulation of ZIKV in Bangla-
desh was recently published,36 there are no peer-reviewed
studies on the seroprevalence of antibodies against ZIKV
in Bangladesh. Studies from surrounding areas indicate
that the seroprevalence of ZIKV will not exceed 20%.11 A
larger study population might thus have been required to
increase the power of the study.
In conclusion, this study in a well-defined cohort of
patients with GBS from Bangladesh provides evidence
that ZIKV infections in an endemic area may trigger a
distinct clinical and electrophysiological subtype of GBS
although the lack of association between ZIKV and GBS
indicates that the risk is low.
Acknowledgments
Suzan Pas is acknowledged for performing excellent molec-
ular diagnostics, Felicity Chandler for virus neutralization
C.H. GeurtsvanKessel et al. Zika Virus and Guillain–Barre Syndrome
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 613
assays, Sandra Scherbeijn for serology (Viroscience, Eras-
mus MC), and Olivia Le Gall (Fondation Merieux) for
administrative and project management support. We are
grateful to Dr. Tanura Sharmin Chowdhury and Dr. Tan-
veen Ishaque for enrollment of patients, follow-up data col-
lection, and arranging transportation of biological
specimens from the hospitals to the ICDDR,B laboratory.
This research project was supported by ICDDR,B and
the Government of Bangladesh. ICDDR,B gratefully
acknowledges the commitment of the Government of Ban-
gladesh to their research efforts, and would like to thank
the following donors for providing unrestricted support:
the Government of the People’s Republic of Bangladesh,
Global Affairs Canada (GAC), the Swedish International
Development Cooperation Agency (Sida), and the Depart-
ment for International Development, UK (DFID).
Author Contributions
CG, ZI, MK, BJ, HE, and CR contributed to the concep-
tion and design of the study; CG, ZI, MI, IS, IJ, QM, SK,
NP, CR, RM, DV, FP, QM, and RP contributed to the
acquisition and analysis of the data; CG, SK, ZI, MI, BJ,
and HE contributed to drafting a significant proportion
of the manuscript or figures.
Conflict of Interest
No conflicts of interest.
References
1. Gatherer D, Kohl A. Zika virus: a previously slow
pandemic spreads rapidly through the Americas. J Gen
Virol 2016;97(2):269–273.
2. Duffy MR, Chen TH, Hancock WT, et al. Zika virus
outbreak on Yap Island, Federated States of Micronesia. N
Engl J Med 2009;360:2536–2543.
3. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus,
French polynesia, South pacific, 2013. Emerg Infect Dis
2014;20:1085–1086.
4. da Silva IRF, Frontera JA, deBispo Filippis AM,
Nascimento O; Group R-G-ZR. Neurologic complications
associated with the Zika virus in Brazilian adults. JAMA
Neurol 2017;74:1190–1198.
5. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre
Syndrome outbreak associated with Zika virus infection in
French Polynesia: a case-control study. Lancet
2016;387:1531–1539.
6. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre
syndrome. Lancet 2016;388:717–727.
7. Dos Santos T, Rodriguez A, Almiron M, et al. Zika Virus
and the Guillain-Barre Syndrome - Case Series from Seven
Countries. N Engl J Med 2016;375:1598–1601.
8. Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-
Barre syndrome associated with Zika virus infection in
Colombia. N Engl J Med 2016;375:1513–1523.
9. Dirlikov E, Major CG, Mayshack M, et al. Guillain-Barre
syndrome during ongoing Zika virus transmission - Puerto
Rico, January 1-July 31, 2016. MMWR Morb Mortal Wkly
Rep 2016;65:910–914.
10. Kindhauser MK, Allen T, Frank V, et al. Zika: the origin
and spread of a mosquito-borne virus. Bull World Health
Organ 2016;94:675–686.
11. Lim SK, Lim JK, Yoon IK. An update on Zika virus in
Asia. Infect Chemother 2017;49:91–100.
12. Duong V, Ong S, Leang R, et al. Low circulation of Zika
virus, Cambodia, 2007–2016. Emerg Infect Dis
2017;23:296–299.
13. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of
Guillain-Barre syndrome and validation of Brighton
criteria. Brain 2014;137(Pt 1):33–43.
14. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The
spectrum of antecedent infections in Guillain-Barre
syndrome: a case-control study. Neurology 1998;51:1110–
1115.
15. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of
Guillain-Barre syndrome associated with Campylobacter
infection in Bangladesh. Neurology 2010;74:581–587.
16. Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-
Barre syndrome following primary cytomegalovirus
infection: a prospective cohort study. Clin Infect Dis
2011;52:837–844.
17. Jacobs BC, van den Berg B, Verboon C, et al. International
Guillain-Barre Syndrome Outcome Study (IGOS): protocol
of a prospective observational cohort study on clinical and
biological predictors of disease course and outcome in
Guillain-Barre syndrome. J Peripher Nerv Syst 2017;22:68–
76.
18. Asbury AK, Cornblath DR. Assessment of current
diagnostic criteria for Guillain-Barre syndrome. Ann
Neurol 1990;27(Suppl):S21–S24.
19. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM.
Controlled trial prednisolone in acute polyneuropathy.
Lancet 1978;2:750–753.
20. Hadden RD, Cornblath DR, Hughes RA, et al.
Electrophysiological classification of Guillain-Barre
syndrome: clinical associations and outcome. Plasma
Exchange/Sandoglobulin Guillain-Barre Syndrome Trial
Group. Ann Neurol 1998;44:780–788.
21. Steinhagen K, Probst C, Radzimski C, et al.
Serodiagnosis of Zika virus (ZIKV) infections by a novel
NS1-based ELISA devoid of cross-reactivity with dengue
virus antibodies: a multicohort study of assay
performance, 2015 to 2016. Euro Surveill 2016;21:
pii30426.
22. Ang CW, Krogfelt K, Herbrink P, et al. Validation of an
ELISA for the diagnosis of recent Campylobacter infections
614 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Zika Virus and Guillain–Barre Syndrome C.H. GeurtsvanKessel et al.
in Guillain-Barre and reactive arthritis patients. Clin
Microbiol Infect 2007;13:915–922.
23. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and
serologic properties of Zika virus associated with an
epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis
2008;14:1232–1239.
24. Arias A, Torres-Tobar L, Hernandez G, et al. Guillain-
Barre syndrome in patients with a recent history of Zika
in Cucuta, Colombia: a descriptive case series of 19
patients from December 2015 to March 2016. J Crit Care
2017;37:19–23.
25. Fontes CA, Dos Santos AA, Marchiori E. Magnetic
resonance imaging findings in Guillain-Barre syndrome
caused by Zika virus infection. Neuroradiology
2016;58:837–838.
26. Oehler E, Watrin L, Larre P, et al. Zika virus infection
complicated by Guillain-Barre syndrome–case report,
French Polynesia, December 2013. Euro Surveill 2014;19:
pii20720.
27. Roze B, Najioullah F, Ferge JL, et al. Zika virus detection
in urine from patients with Guillain-Barre syndrome on
Martinique, January 2016. Euro Surveill 2016;21:30154.
28. Lustig Y, Mendelson E, Paran N, et al. Detection of Zika
virus RNA in whole blood of imported Zika virus disease
cases up to 2 months after symptom onset, Israel,
December 2015 to April 2016. Euro Surveill 2016;21:1–4.
29. L’Huillier AG, Hamid-Allie A, Kristjanson E, et al.
Evaluation of euroimmun anti-Zika virus IgM and
IgG enzyme-linked immunosorbent assays for Zika
virus serologic testing. J Clin Microbiol 2017;55:2462–
2471.
30. Granger D, Hilgart H, Misner L, et al. Serologic testing for
Zika virus: comparison of three Zika virus IgM-screening
enzyme-linked immunosorbent assays and initial laboratory
experiences. J Clin Microbiol 2017;55:2127–2136.
31. Vatti A, Monsalve DM, Pacheco Y, et al. Original
antigenic sin: a comprehensive review. J Autoimmun
2017;83:12–21.
32. Barzon L, Percivalle E, Pacenti M, et al. Virus and
antibody dynamics in travelers with acute zika virus
infection. Clin Infect Dis 2017. doi: 10.1093/cid/cix967.
[Epub ahead of print].
33. Lustig Y, Cotar AI, Ceianu CS, et al. Lack of Zika virus
antibody response in confirmed patients in non-endemic
countries. J Clin Virol 2017;21:31–34.
34. van Meer MPA, Mogling R, Klaasse J, et al. Re-evaluation
of routine dengue virus serology in travelers in the era of
Zika virus emergence. J Clin Virol 2017;03:25–31.
35. Frontera JA, da Silva IR. Zika getting on your nerves? The
association with the Guillain-Barre syndrome. N Engl J
Med 2016;375:1581–1582.
36. Muraduzzaman AKM, Sultana S, Shirin T, et al.
Introduction of Zika virus in Bangladesh: an impending
public health threat. Asian Pac J Trop Med 2017;10:
925–928.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 615
C.H. GeurtsvanKessel et al. Zika Virus and Guillain–Barre Syndrome
